Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Polli

Showing results (21-30 of 420) with videos related to

Pageof 42
Sort By:
The AAPS Journal|January 6, 2022
Evaluation of Excipient Risk in BCS Class I and III BiowaiversMelissa Metry, James E Polli
Annali Italiani Di Medicina Interna : Organo Ufficiale Della Societa Italiana Di Medicina Interna|January 1, 1989
[Postmarketing surveillance of adverse reactions of drugs]E E Polli, M Cortellaro
Haematologica|June 1, 1980
Present status of antiaggregating agents in coronary and cerebrovascular disease preventionE E Polli, M Cortellaro
The Journal of Pharmacology and Experimental Therapeutics|April 30, 2008
Impact of impurity on kinetic estimates from transport and inhibition studiesPablo González, James E Polli
Thrombosis Research|January 1, 1979
On the inhibiting effect of sulfinpyrazone on plateletsM Cortellaro, E E Polli
Journal of Pharmaceutical Sciences|April 2, 2011
Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2Lei Diao, James E Polli
Haematologica|March 1, 1974
Cell growth cycle and expression of histocompatibility antigens on cultured human lymphoid cellsS Ferrone, E E Polli
Journal of the American Pharmacists Association : Japha|May 19, 2007
Evaluation of a novel tablet splitterJing Shao, James E Polli
Molecular Pharmaceutics|June 6, 2006
Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug targetAnand Balakrishnan, James E Polli
Annali Italiani Di Medicina Interna : Organo Ufficiale Della Societa Italiana Di Medicina Interna|January 1, 1991
[Hematopoietic tissue growth factors: clinical factors]E E Polli, P Foa
Pageof 42

Showing results (21-30 of 420) with videos related to

Sort By:
Pageof 42
The AAPS Journal|January 6, 2022
Evaluation of Excipient Risk in BCS Class I and III BiowaiversMelissa Metry, James E Polli
Annali Italiani Di Medicina Interna : Organo Ufficiale Della Societa Italiana Di Medicina Interna|January 1, 1989
[Postmarketing surveillance of adverse reactions of drugs]E E Polli, M Cortellaro
Haematologica|June 1, 1980
Present status of antiaggregating agents in coronary and cerebrovascular disease preventionE E Polli, M Cortellaro
The Journal of Pharmacology and Experimental Therapeutics|April 30, 2008
Impact of impurity on kinetic estimates from transport and inhibition studiesPablo González, James E Polli
Thrombosis Research|January 1, 1979
On the inhibiting effect of sulfinpyrazone on plateletsM Cortellaro, E E Polli
Journal of Pharmaceutical Sciences|April 2, 2011
Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2Lei Diao, James E Polli
Haematologica|March 1, 1974
Cell growth cycle and expression of histocompatibility antigens on cultured human lymphoid cellsS Ferrone, E E Polli
Journal of the American Pharmacists Association : Japha|May 19, 2007
Evaluation of a novel tablet splitterJing Shao, James E Polli
Molecular Pharmaceutics|June 6, 2006
Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug targetAnand Balakrishnan, James E Polli
Annali Italiani Di Medicina Interna : Organo Ufficiale Della Societa Italiana Di Medicina Interna|January 1, 1991
[Hematopoietic tissue growth factors: clinical factors]E E Polli, P Foa
Pageof 42